Email
Tracking the latest news and developments across our global network
|
FUJIFILM Biotechnologies is proud to be an innovative CDMO partner, seamlessly guiding our customers though their journey of creating life-impacting medicines from initial process development stages through to full commercial supply. Catch up on our latest news and insights below.
|
|
|
During a busy week at JPM 2026, Lars Petersen, President & CEO of FUJIFILM Biotechnologies, joined the Endpoints panel, “Manufacturing During Global Policy Uncertainty,” alongside: Karin Shanahan, EVP, Chief Supply Chain & Operations Officer, Bristol Myers Squibb, and Victor Bulto, President, Novartis US for a lively discussion moderated by Drew Armstrong, Executive Editor, Endpoints News.
The discussion centered around one of the most critical issues facing our industry: how to manage manufacturing strategy and supply chains in times of uncertainty. They explored how standardization, industrialization, and collaboration are essential enablers of resilience and agility in biopharmaceutical manufacturing. At the discussion, Lars shared how the pandemic exposed the
fragility of moving products across a global supply chain when regions and systems aren’t aligned and pushed for ecosystem-based models, standardization and deepening trust between innovators and partners to future-proof manufacturing.
|
|
|
Late Stage / Clinical Solutions
|
|
| Accelerating CMC Programs
|
|
|
Explore new strategies for reducing late-phase CMC timelines for mammalian and microbial-derived therapeutic proteins in our recent webinar.
|
|
|
| Strengthen Your CMC Packages
|
|
|
|
Interested in practical guidance for outsourcing Process Characterization (PC) to strengthen your CMC packages and accelerate commercialization? View our whitepaper below.
|
|
|
| Clinical to Commercial Readiness
|
|
|
Looking for analytical solutions to support your clinical programs and preparation for commercial manufacturing?
|
|
|
|
Catch up on some of the most recent stories:
|
|
|
- FUJIFILM Corporation recently announced the completion of one of Japan’s largest bio CDMO facilities at the Toyama site of FUJIFILM Toyama Chemical. The new plant is the company’s first antibody drug manufacturing plant with ADC capabilities, leveraging Fujifilm’s longstanding expertise in API and specialty handling. Located in Japan, it is scheduled to be operational in 2027. Read the press release
- During JPM 2026, Fujifilm’s President, Representative Director & CEO, Teiichi Goto, spoke with Fierce Pharma about Fujifilm’s investments in the CDMO business, why they decided to build capacity instead of buying existing facilities, and where the company is headed next. Read the article
- Pharma Navigator interviewed our Chief Strategy Officer Maria Andreasen as JPM was about to kick off to anticipate some of the conference conversations around onshoring, artificial intelligence (AI), and key operational priorities for the bio/pharma industry in 2026 and beyond. Read the full interview
- In a recent article from Pharma Manufacturing, FUJIFILM Biotechnologies is listed as one of the top CDMOs to watch in 2026 and is poised to have a big impact this year on the biopharma industry. Read the full article
|
|
Advanced Therapies Week USA
|
|
February 9-12, 2026 | Convention Center, San Diego
|
|
|
Fujifilm will be attending Advanced Therapies Week USA in February 2026. Be sure to stop by, attend our panel sessions or find us at Booth #233 to learn about our cell and gene therapy solutions, services and expertise. Come visit us to learn more about our latest innovations.
|
|
|
Fujifilm’s Panel Sessions During ATW 2026:
|
|
February 11, 8:00 a.m. – Theatre 1
Join Yosuke Kurokawa, Senior Scientist, R&D Cell Therapy – FUJIFILM Biosciences as part of a panel to discuss “Building Scalable Cell Therapy Workflows: Media, Process, and Automation in Action“.
|
|
|
Clinical and Translational Excellence
|
|
|
February 11, 4:00 p.m. – Theatre 3
Amanda Cinquin, Senior Manager Regulatory Affairs & Technical Investigations at FUJIFILM Biosciences will be discussing “Standardizing material management in cell and gene therapy: a consensus framework for quality, risk, and regulatory alignment“.
|
|
|
March 23-26 2026 | New York City
|
|
|
FUJIFILM Biotechnologies will be attending DCAT Week in New York City, the premier event for the global Bio/Pharmaceutical industry. Connect with our team to discuss strategic partnerships and learn how our end-to-end biomanufacturing solutions can support your programs.
|
|
|
FUJIFILM Biotechnologies
101 J Morris Commons Ln Ste 135
Morrisville, North Carolina 27560
|
|
|
Unsubscribe
101 J Morris Commons Ln
Morrisville, NC 27560
|
|
|
|
|
